Every month we shine a spotlight on cutting-edge research being supported by the CTSO at Michigan Medicine. Below you will find all of the exciting trials we have profiled so far. Click here and subscribe to receive the latest Clinical Trials Spotlights each month.
ALL FEATURED SPOTLIGHTS
The Ambulatory & Chronic Disease CTSU is supporting a trial studying Lupus Nephritis led by Principal Investigator, Patricia Cagnoli, MD. Sponsored by Bristol-Myers Squibb and part of The Paisley Study, Dr. Cagnoli is evaluating the safety and effectiveness of an investigational drug versus placebo in regards to kidney function in subjects with Lupus Nephritis. LEARN MORE.
The Oncology CTSU is supporting a first-in-human study evaluating the efficacy of an irreversible oral inhibitor of the oncogene KRAS G12c, led by Principal Investigator John C. Krauss, MD, and supported by O-CTSU Study Coordinators Dominique Dippman and Kate Moran. LEARN MORE.
The Acute, Critical Care, Surgery, & Transplant CTSU is currently supporting the MEDEOR MDR-101-MLK trial. Led by Principal Investigator, Randall Sung, MD – Department of Surgery, MEDEOR is a multi-center, phase 3 trial assessing the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA matched, a living donor kidney transplant. LEARN MORE.
Principal Investigator, Vallerie McLaughlin, M.D. is currently working on the Phase 2 PULSAR study supported by the HVB CTSU. PULSAR is looking to compare Sotatercept versus placebo in treating pulmonary arterial hypertension (PAH). PAH is a rare condition resulting from obstruction of the small arteries in the lung, causing high blood pressure. This condition impacts fewer than 200,000 people in the United States. LEARN MORE.
The Neurosciences and Sensory (NSS) CTSU is currently supporting a clinical trial led by Principal Investigator, Tiffany Braley, MD, that is looking into how Continuous Positive Airway Pressure (CPAP) therapy can improve cognitive function in patients with Multiple Sclerosis (MS). LEARN MORE.
The Children’s CTSU is currently supporting a Phase III trial studying the drug Edasalonexent (Edasa) in pediatric patients with Duchenne Muscular Dystrophy (DMD). Sponsored by Catabasis and lead by Principal Investigator Erin Neil Knierbein, DO, and Children's CTSU Study Coordinator Amy Hurst, this randomized, double-blind, and placebo-controlled study is attempting to determine the effectiveness of Edasa in reducing the symptoms of DMD and its ability to slow down the disease progression. LEARN MORE.
The Ambulatory and Chronic Disease CTSU is currently supporting the Phase III investigational drug and device trial, VeraCept, sponsored by Sebela Pharmaceuticals Inc. VeraCept is a new Intrauterine Device (IUD) that is a flexible, hormone-free, low-dose copper device designed to prevent pregnancy. LEARN MORE.
The Oncology CTSU is currently supporting a Non-randomized, Open-label Dose-finding Trial of Combined Cytotoxic and Immune-stimulatory Strategy for the Treatment of Resectable Primary Malignant Glioma. Malignant Glioma is a rare disease impacting less than 200,000 people per year. Glioma cells are one of the most aggressive and malignant tumors with a median survival rate of 14-20 months post-diagnosis. LEARN MORE.
The Acute, Critical Care, Surgery and Transplant CTSU is thrilled to be supporting the ACCESS trial which will compare two current standards of care for treating resuscitated adult patients who suffered an out-of-hospital ventricular fibrillation (V-Fib) cardiac arrest. The ACCESS Trial, led by Co-Investigators, Michael Thomas, MD and Cindy Hsu, PhD, will include adult victims of V-Fib out-of-hospital cardiac arrest who are transported to Michigan Medicine. LEARN MORE.
The Behavior, Function & Pain CTSU is supporting a new clinical trial, currently referred to as Fibrolight, led by Principal Investigator Helen Burgess, PhD, that uses bright light therapy to improve symptom management of fibromyalgia syndrome. LEARN MORE.
The Heart, Vessel, Blood CTSU is supporting two interventional studies sponsored by MyoKardia in Phase 2 and Phase 3 development. The drug Mavacamten, is being studied in adults with Symptomatic Non-Obstructive (nHCM) and Obstructive (oHCM) Hypertrophic Cardiomyopathy. LEARN MORE.
The Neurosciences & Sensory CTSU is currently supporting an exciting Phase 2, interventional study working to treat plaque psoriasis. Lead by PI Johann Gudjonsson, MD, PhD, Derm 677: Psoriasis and Riboflavin, is looking to determine the anti-inflammatory effect of high-dose riboflavin (also known as Vitamin B2) on chronic plaque psoriasis. LEARN MORE.
This summer and recently highlighted in The New York Times, three new clinical trials for Hemophilia A opened to enrollment, led by Dr. Steven Pipe and coordinated by the Children's CTSU. Sponsored by BioMarin, the trials offer patients a single infusion of a gene therapy product that has the potential to lessen or eliminate the symptoms of their Hemophilia A for years to come. LEARN MORE.
The Acute, Critical Care, Surgery and Transplant (ACCST) CTSU is currently supporting the exciting new study, Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS), led by Robert Hyzy, MD, Medical Director of ACCST. LEARN MORE.
The Ambulatory & Chronic Disease (ACD) CTSU is happy to announce that the first patient at the University of Michigan has been enrolled in the pivotal Phase 3 FOCuS clinical trial evaluating WTX101, an investigational first-in-class copper-protein-binding agent with a unique mechanism of action for the treatment of Wilson's Disease. LEARN MORE.
The Oncology CTSU is currently supporting a unique initial phase immunotherapy trial for rare cancers funded by the National Cancer Institute. Lead by Principal Investigator Mark Michael Zalupski, M.D., DART (Dual Anti-CTLA-4 and Anti¬-PD-1 Blockade in Rare Tumors) is a multisite trial that focuses on rare cancers, which make up more than 20% of cancers diagnosed worldwide, and include, but are not limited to, cancers in nerves, glands, bones, and skin. LEARN MORE.
Exciting things are happening in the Behavior, Function and Pain Clinical Trials Support Unit (BFP CTSU). A new trial lead by Dr. Afton Hassett, Promoting Resilience Through Innovative Self-Management (PRISM), is working to better manage chronic neck and back pain (i.e. chronic spine pain). LEARN MORE.
It's American Heart Month! American Heart Month is a federally designated event to remind Americans to focus on their cardiovascular wellbeing. More than 2,300 Americans die of cardiovascular disease every day. The Heart, Vessel, & Blood Clinical Trials Support Unit (HVB CTSU) at Michigan Medicine is actively supporting studies to improve patient heart health! LEARN MORE.
A new study led by Susan Shore, PhD, based in the Department of Otolaryngology at Michigan Medicine, will be joining the Neurosciences & Sensory (NSS) CTSU for Phase II of their trial. Phase I of her study shows that an experimental device could help quiet the phantom sounds caused by Tinnitus by targeting unruly nerve activity in the brain. LEARN MORE.